

WHAT ARE ORTHOBIOLOGICS?

- 1 Less invasive needle based, medical specialty
- 2 Patients bone marrow concentrate and platelet rich plasma
- 3 Lower risk alternative to surgery




Not stem cell therapy · Not gene therapy · Not lab-grown cells

Bone marrow concentrate


- ✓ Source of your stem cells
- ✓ Concentrated on site
- ✓ Reinjecting back into damaged tissue on the same day

Bone Marrow Aspiration



Platelet/Platelet Rich Plasma (PRP)

- ✓ Blood draw
- ✓ Cells concentrated on site
- ✓ Reinjecting back into your damaged tissue on the same day



MarineMax Experience:

Better Outcomes. Lower Cost. Faster Return to Work.

OUTCOMES

143

employees treated | 6+ years

167 procedures completed across 2,707 covered lives

Surgical alternatives: knees, spine, shoulders, hips, elbows, ankles, hands & wrists

Candidacy discipline: Poor candidates not treated — many routed to conservative care first

Validation Institute Certified | 49% savings methodology



FINANCIAL IMPACT

\$1,735,783

estimated savings since program launch vs. Healthcare Bluebook surgical benchmarks

Surgery avg

\$16,200 avg surgical episode

Regenexx avg

\$5,912 avg procedure

64% savings rate vs. equivalent surgical fair market value (\$2,723,155 avoided)

Return to work

Executive Summary

This analysis summarizes time away from work following *orthobiologic* procedures using registry data. Only records with a reported value for workdays missed were included, and only patients reporting current employment status were analyzed.

0

Median Days Missed

The median patient missed 0 days (IQR 0-1)

74.6%

Zero Days Missed

Percentage of patients who reported 0 days missed

1.62

Mean Days Missed

Average days missed (n=3557)



The Orthobiologics Approach vs. Elective Orthopedic Surgery

7 years of commercial insurance claims · Propensity-matched cohort · IRB Approved · Lentz et al., 2026

Spinal Fusion

\$45,616

per-patient savings vs. surgery

<1%

Regenexx re-procedure
48 months

14%

Surgery re-operation
48 months

Lumbar Decompression

\$19,317

per-patient savings over 48 months

<5%

Regenexx re-procedure
48 months

27%

Surgery re-operation
48 months

Knee Replacement (TKA)

\$13,556

per-patient savings over 12 months

8.5%

Regenexx TKA conversion
48 months

11.3%

Surgery own revision
12 months

Knee Meniscectomy

\$5,044

per-patient savings over 48 months

<6.7%

Regenexx repeat procedure
48 months

>11%

Surgery repeat rate
48 months

Additional outcomes vs. knee replacement (TKA):

36% fewer outpatient visits (4.6 vs. 7.2)

37% fewer PT visits (10.1 vs. 15.9)

22% lower opioid Rx rate (35% vs. 44%)